Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Express Scripts

Last Updated: December 3, 2021

DrugPatentWatch Database Preview

Patent: 7,560,100

➤ Subscribe for complete access

« Back to Dashboard

Summary for Patent: 7,560,100
Title:Mixtures of polypeptides, compositions containing and processes for preparing same, for treating neurodegenerative diseases
Abstract: The invention provides a composition comprising a mixture of polypeptides, wherein each polypeptide (a) is a copolymer of the amino acids L-glutamic acid, L-alanine, L-tyrosine, and L-lysine, and (b) may be in the form of a pharmaceutically acceptable salt; and wherein in the mixture (i) the polypeptides have an average molecular weight in the range 13,500 to 18,500 daltons, (ii) 13% to 38% of the polypeptides have a diethylamide group instead of a carboxyl group present at one end thereof, and (iii) 68% of the polypeptides have a molecular weight between 7,000 and 41,000 daltons. In an embodiment, the average molecular weight is 16,000 daltons. The invention also provides a method of treating a human subject afflicted with a neurodegenerative disease comprising administering to the human subject a therapeutically effective amount of any of the disclosed compositions so as to thereby treat the human subject.
Inventor(s): Pinchasi; Irit (Ra\'anana, IL), Dolitzky; Ben-Zion (Petach-Tikva, IL), Frenkel; Anton (Modiin, IL), Schwartz; Michal (Rehovot, IL), Arnon; Ruth (Rehovot, IL), Aharoni; Rina (Rehovot, IL)
Assignee: Yeda Research and Development Co., Ltd. (Rehovot, IL)
Application Number:11/223,408
Patent Claims:see list of patent claims

Details for Patent 7,560,100

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Genzyme Corporation CAMPATH alemtuzumab Injection 103948 2001-05-07 ⤷  Try it Free 2024-09-09
Genzyme Corporation LEMTRADA alemtuzumab Injection 103948 2014-11-14 ⤷  Try it Free 2024-09-09
Genzyme Corporation CAMPATH alemtuzumab Injection 103948 2004-10-12 ⤷  Try it Free 2024-09-09
Biogen Inc. TYSABRI natalizumab Injection 125104 2004-11-23 ⤷  Try it Free 2024-09-09
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Express Scripts
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.